Core Insights - Nexentis Technologies Inc. has launched a new corporate website following its rebranding from N2OFF, Inc., emphasizing its focus on mitochondrial biology for advancements in precision oncology and inflammatory metabolic diseases [2][4] - The website serves as a hub for stakeholders, showcasing the proprietary MITOLINE™ discovery engine and the integration of MitoCareX Bio Ltd., which targets the mitochondrial SLC25 carrier family for drug development [3][6] - The company is also investing in solar energy assets under the Ready-to-Build (RTB) model, highlighting a balanced approach to value creation [3][6] Company Overview - Nexentis Technologies Inc. is a drug discovery company focused on cancer and inflammatory metabolic diseases, controlling 100% of MitoCareX Bio Ltd. [6] - The company has adopted an investment strategy in European renewable energy assets, currently leading four solar projects across three EU countries [6] - Nexentis also holds approximately 98% of Save Foods Ltd., which specializes in post-harvest treatment technologies to reduce pathogen contamination in fruits and vegetables [7]
Nexentis Technologies Inc. Launches New Corporate Website, Showcasing Innovative AI-Driven Biotech Platform
Globenewswire·2026-03-13 13:15